HACRO President Evangelia (Lia) Koraki participated in the panel discussion “Artificial Intelligence, Clinical Trials and the Pharmaceutical Industry” at the 7th Panhellenic Conference on Clinical Trials and Research, organised by the Hellenic Association of Pharmaceutical Industry Representatives (SAFEE).
During the discussion, Ms Koraki stressed that responsible innovation cannot exist without clinical trials. Clinical research is the essential pathway through which innovative therapies reach patients, while also providing the most reliable insight into patients’ unmet medical needs particularly in the face of an ageing population and the growing prevalence of chronic and rare diseases.
Although Europe continues to face increasing global competition in attracting clinical trials, Greece currently ranks 13th among 28 European countries, demonstrating significant potential for further growth. To fully realise this opportunity, clinical research must become a clear national priority, supported by long-term strategic planning, targeted investment, effective public-private collaboration and stronger incentives, including the further enhancement of the clawback offset scheme for clinical trial investments.
Ms Koraki also highlighted the transformative role of artificial intelligence in clinical research. Rather than replacing scientists, AI serves as a powerful enabler—accelerating processes, strengthening quality and patient safety, improving protocol design, and significantly enhancing patient identification and recruitment, ultimately facilitating faster access to innovative therapies.
The discussion concluded with a shared recognition that Greece has the opportunity to become an increasingly attractive destination for international clinical research. Achieving this goal will require sustained reforms, a clear national strategy and continued investment in innovation.